PDS Biotechnology grants 150,000 options to CSO

PDS Biotechnology Corp reported that Chief Scientific Officer Gregory Conn received an employee stock option grant covering 150,000 shares on January 12, 2026.

Rhea-AI Filing Summary

PDS Biotechnology Corp reported that Chief Scientific Officer Gregory Conn received an employee stock option grant covering 150,000 shares on January 12, 2026. The option was awarded at an exercise price of $0.00 per share.

According to the vesting terms, 25% of the underlying shares will vest and become exercisable on January 12, 2027. The remaining 75% will vest in 36 equal monthly installments after that date, contingent on Conn’s continued service with the company through each vesting date.

Insider Trade Summary

Grant/Award: 150,000 shares

Grant/Award 1 txn

Insider CONN GREGORY

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	150,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 150,000 contracts (Direct)

Footnotes (1)

1. F1. The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PDSB report for Chief Scientific Officer Gregory Conn?

PDS Biotechnology reported that Chief Scientific Officer Gregory Conn received an employee stock option grant for 150,000 shares on January 12, 2026. The Form 4 describes this as a grant or award acquisition, with the options held directly by Conn, rather than through an intermediary entity.

How many options were granted to Gregory Conn in the latest PDSB Form 4?

Gregory Conn was granted employee stock options covering 150,000 shares of PDS Biotechnology common stock. All 150,000 options are shown as directly owned following the transaction, reflecting a new award rather than a partial change to a pre-existing option position for the Chief Scientific Officer.

What is the vesting schedule for Gregory Conn’s 150,000 PDSB stock options?

The options vest over four years. Twenty-five percent of the shares vest and become exercisable on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments. Vesting depends on Conn’s continued service with PDS Biotechnology through each scheduled vesting date.

Was Gregory Conn’s Form 4 transaction in PDSB stock a purchase or a grant?

The transaction was a grant of stock options, not an open-market share purchase. The Form 4 classifies it as a grant, award, or other acquisition, giving Conn the right to buy 150,000 shares under an employee stock option arrangement rather than immediately acquiring common shares.

What role does Gregory Conn hold at PDS Biotechnology Corp (PDSB)?

Gregory Conn serves as Chief Scientific Officer at PDS Biotechnology Corp. The Form 4 identifies him as an officer, not a director or ten percent owner, and reports his receipt of a 150,000-share employee stock option award under the company’s equity compensation framework.

Are Gregory Conn’s newly granted PDSB options subject to any service conditions?

Yes, the vesting of Gregory Conn’s stock options depends on continued service. The footnote states that each vesting date requires his continued service to PDS Biotechnology, meaning unvested portions would not vest if his service ended before the applicable vesting dates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 06:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CONN GREGORY

(Last) (First) (Middle)

C/O PDS BIOTECHNOLOGY CORPORATION

303A COLLEGE ROAD EAST

(Street)

PRINCETON NJ 07922

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PDS Biotechnology Corp [ PDSB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$0.98	01/12/2026		A		150,000		(1)	01/12/2036	Common Stock	150,000	$0	150,000	D

Explanation of Responses:

1. The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.

	/s/ Spencer Brown, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.